企業概要
NewcelX Ltd. is a biotechnology enterprise dedicated to the development of transformative cell-based and small-molecule therapies targeting neurodegenerative and metabolic diseases. The company operates within the healthcare sector, specifically in the biotechnology industry, which implies a focus on high-risk, high-reward research and development with potential for significant clinical impact. As of the latest data, NewcelX Ltd. maintains a market capitalization of $9.53M and employs 11 individuals, while specific annual revenue figures are not disclosed in the available financial statements. The combination of a sub-$10M market cap and a lack of reported revenue indicates that the company is in an early-stage development phase, where capital is primarily allocated toward research and development activities rather than commercialization and sales operations.
財務健全性
The company reports Net Income and Revenue for the trailing twelve months as N/A, reflecting the typical financial profile of pre-revenue biotechnology firms where earnings are often negative or non-existent due to heavy R&D expenditures. The EBITDA stands at $-9,115,000, indicating that operating losses are substantial, which is consistent with the cost structure of a company heavily invested in scientific discovery rather than profit generation. Despite the negative EBITDA, the Free Cash Flow is reported as $37.31M, a figure that suggests the company possesses significant financial flexibility, likely supported by cash reserves from prior financing rounds or asset sales not detailed in the current cash balance line. The Gross Margin, Operating Margin, and Profit Margin are all recorded at 0.0%, which indicates that the company has not yet generated profitable sales; at this stage, the lack of gross profit is expected as costs are focused on product development rather than manufacturing margins. Regarding liquidity and leverage, the available data lists Cash as N/A and Debt as N/A, meaning specific comparisons of total cash versus total debt cannot be numerically calculated from the provided facts. However, the Current Ratio is 0.02, a critically low figure that indicates severe short-term liquidity constraints, suggesting that current liabilities significantly outweigh current assets without the intervention of external capital or asset monetization. Furthermore, the Return on Equity is N/A and the Return on Assets is -155.2%, metrics that reveal management is currently deploying capital to generate negative returns, a common characteristic of biotech startups before clinical milestones are achieved.
バリュエーション評価
The Trailing P/E and Forward P/E ratios are both listed as N/A, which implies that the company does not have sufficient earnings to calculate a traditional multiple, rendering standard earnings-based valuation models inapplicable for assessing expected earnings trajectories. The Price to Book ratio is -0.19, a negative figure that indicates the market values the company at less than its book value, often seen in biotech firms where intangible assets like intellectual property are not fully captured on the balance sheet or where liabilities exceed assets on a GAAP basis. Since Revenue is N/A, the Price to Sales ratio is also N/A, and similarly, the EV/EBITDA is N/A, suggesting that alternative valuation metrics relying on sales or operating leverage are currently unavailable for analysis. The stock has a 52-Week High of $30.80 and a 52-Week Low of $1.83, defining a wide trading range typical of volatile small-cap biotechnology equities. The Beta of 0.57 indicates that the stock price is less volatile than the broader market, suggesting that despite the wide price range, the equity has historically moved with less intensity than the S&P 500.
Growth & Income
Revenue Growth and Earnings Growth for the year-over-year period are both listed as N/A, preventing a direct calculation of whether earnings are growing faster or slower than revenue due to the absence of baseline sales data. As the company does not distribute dividends, the Dividend Yield and Payout Ratio are both N/A or 0.0%, indicating that NewcelX Ltd. follows a strategy of reinvesting all available resources into research, development, and operational expansion rather than returning capital to shareholders. This non-dividend approach is standard for early-stage biotechnology companies, where the primary objective is to fund clinical trials and regulatory submissions to advance their therapeutic pipeline. Consequently, the overall growth and income profile is characterized by a complete absence of current income generation, with value entirely contingent on the potential future success of their cell-based and small-molecule therapies for neurodegenerative and metabolic diseases.